Uterine carcinosarcoma
MONDO:0006485A usually aggressive malignant neoplasm arising from the uterine corpus and less often the cervix. It is characterized by the presence of two components: a malignant epithelial component and a sarcomatous component. In the uterine corpus the epithelial component is usually glandular whereas in the cervix is usually non-glandular. Carcinosarcoma of the cervix, although it is aggressive, it may have a better prognosis compared to the uterine corpus carcinosarcoma.
Also known as: carcinosarcoma of the uterus, malignant mixed mesodermal (Mullerian) tumor of the uterus, malignant mixed mesodermal (Mullerian) tumour of the uterus, malignant mixed mesodermal (Müllerian) tumor of the uterus, malignant mixed mesodermal (Müllerian) tumour of the uterus, uterine carcinosarcoma, uterine malignant mixed mesodermal (Mullerian) tumor, uterine malignant mixed mesodermal (Mullerian) tumour
2863 clinical trials for this condition and its sub-types, 23 tagged with Uterine carcinosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Uterine carcinosarcoma
-
Carcinosarcoma of the corpus uteri 13 trials
-
Cervical carcinosarcoma 0 trials
-
Can a Two-Drug combo tame a rare and aggressive gynecologic cancer?
Disease control CompletedThis phase II trial is testing whether the chemotherapy drug eribulin, given alone or combined with the immunotherapy pembrolizumab, can help people with ovarian or uterine carcinosarcoma that has returned or progressed. The study aims to see if these treatments can shrink tumors…
Phase 2 • Sponsor: Australia New Zealand Gynaecological Oncology Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New HIV vaccine and antibody cocktail aims to free patients from daily meds
Disease control CompletedThis study tested a two-part vaccine (Ad26.Mos4.HIV and MVA-BN-HIV) combined with three broadly neutralizing antibodies (PGT121, PGDM1400, VRC07-523LS) in 28 adults with HIV who were already on suppressive antiretroviral therapy (ART). The goal was to see if this combination coul…
Phase 1/2 • Sponsor: Boris Juelg, MD PhD • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control CompletedThis phase II trial tested whether combining two drugs, pembrolizumab and olaparib, could help people with persistent or recurrent endometrial cancer or carcinosarcoma. The study enrolled 26 participants and looked at how many responded to treatment and what side effects occurred…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug cocktail shows promise for Tough-to-Treat uterine cancer
Disease control CompletedThis phase 2 trial tested a combination of three drugs—rucaparib, bevacizumab, and atezolizumab—in 30 people with recurrent or progressive endometrial cancer that had not responded to prior treatments. The goal was to see if the combination could shrink tumors or slow the cancer'…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called RP-6306 in 28 people with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also looked for specific biomarkers to see if some patients respond bett…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Shorter radiation after hysterectomy shows promise for endometrial cancer
Disease control CompletedThis study tested a shorter course of pelvic radiation (about 1 week instead of the usual 5-6 weeks) given after hysterectomy for advanced endometrial cancer. The goal was to see if this shorter treatment causes fewer side effects while still controlling the cancer. The study inc…
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC